Share this article

 Email

 Print

 

Republish this article

The text of this article by Futurity is licensed under a Creative Commons Attribution-No Derivatives License.

More
Health & Medicine

Gene makes heart stronger without exercise

Tough guts of female mice point to colitis

To protect jockeys, protect horses first

Block nerve ‘sprouts’ to ease arthritis pain

Paid sick days would slow down flu at work

Lower risk of hypertension for seniors who volunteer

Chip diagnoses infection in minutes, not days

Mom’s PCB exposure harms unborn baby

After abuse, mental health often goes untreated

The new class of drug treatment is about to commence clinical trials, as the result of a decade-long investigation by Ray Norton, a professor at Monash University, and his collaborators, who in the mid 1990s found a component of venom called ShK in the Caribbean sea anemone.

ShK blocks the Kv1.3 potassium channel located in white blood cells, known as T-cells, which are known to produce nerve damage in MS, one of the most common and debilitating diseases of the nervous system.

Norton has since collaborated with a team of scientists in the United States investigating potassium channels as targets for the development of novel immunosuppressive agents.

With potassium channels controlling all sorts of key functions in the human body, developing a drug without unwanted side effects would have been impossible had it not turned out that the Kv1.3 potassium channel is found only on T-cells and in the nose.

Because of this limited distribution, the researchers were able to develop a highly selective immune suppressant derived from the sea anemone peptide.

Norton says that by blocking the potassium channels, ShK prevented the T-cells from attacking the nervous system and causing the paralysis observed in MS patients.

“This research shows that we may be able to effectively treat the disease while protecting the immune system,” adds Norton.

“Continuously blocking these T-cell channels with ShK should prevent further nerve damage, even after the initial onset of symptoms, including paralysis. If the clinical trials are successful, this could prove an effective treatment for MS.”

Norton says ShK is one of the most potent inhibitors known for these channels.

“The next step is to find out what dose works best to treat MS and at what stage of the disease treatment should begin,” says Norton.

More news from Monash University: www.monash.edu.au/news/